Evaluating microRNA-10b levels in glioma patients
Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas
This study is testing if levels of a specific molecule called microRNA-10b in glioma patients can help doctors understand the disease better and predict how it will progress.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dartmouth-Hitchcock Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Boston, Massachusetts and 3 other locations) |
| Trial ID | NCT01849952 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the expression levels of microRNA-10b in patients diagnosed with various types of gliomas, including astrocytomas and oligodendrogliomas. The researchers hypothesize that the expression patterns of miRNA-10b can serve as both prognostic and diagnostic markers for gliomas. Additionally, the study will explore the phenotypic and genotypic diversity of glioma subclasses and evaluate the sensitivity of individual primary tumors to anti-mir-10b treatment in vitro. Tumor, blood, and cerebrospinal fluid samples will be collected from participants over a two-year period for analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have a confirmed diagnosis of glial tumors requiring surgical resection.
Not a fit: Patients with non-glial brain tumors or those who do not have adequate tissue available for processing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the prognostic and diagnostic potential of miRNA-10b in glioma patients.
How similar studies have performed: While the specific approach of evaluating miRNA-10b in gliomas may be novel, similar studies have shown promise in using microRNA as biomarkers in various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion/Exclusion Criteria: * 18 years of age * Brain tumor(s) to be resected for clinical reasons. * Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV. * Adequate tissue available for processing as determined by Pathology. * Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment. * Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.
Where this trial is running
Boston, Massachusetts and 3 other locations
- Tufts Medical Center — Boston, Massachusetts, United States (Active_not_recruiting)
- Massachusetts General Hospital — Boston, Massachusetts, United States (Active_not_recruiting)
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States (Recruiting)
- University of Vermont — Burlington, Vermont, United States (Active_not_recruiting)
Study contacts
- Principal investigator: Arti B Gaur, PhD — Dartmouth-Hitchcock Medical Center
- Study coordinator: Charlotte Esancy
- Email: charlotte.a.esancy@hitchcock.org
- Phone: 6036530619
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.